Short interest in Halozyme Therapeutics Inc (NASDAQ:HALO) decreased during the last reporting period, falling from 10.45M to 8.57M. This put 9.16% of the company's publicly available shares short.

Short interest for Halozyme Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Halozyme Therapeutics's stock. Short interest data is updated every two weeks.

Based on the recent average volume of 2.56M shares traded per day, it would take 3.35 day(s) for holders of this short interest to close out their positions without sending the stock sharply higher.